SOURCE: MELA Sciences

MELA Sciences

January 11, 2011 17:21 ET

Due to Pending Snow Storm and Flight Cancellations, MELA Sciences Cancels Presentation at 13th Annual Needham Growth Conference

IRVINGTON, NY--(Marketwire - January 11, 2011) - MELA Sciences, Inc. (NASDAQ: MELA) today announced that Joseph V. Gulfo, MD, President and CEO, will be unable to present at the 13th Annual Needham Growth Conference. Flight cancellations in advance of the snow storm predicted for the East Coast have impacted his travel plans back from San Francisco.

Dr. Gulfo's presentation was scheduled for Wednesday, January 12, 2011 at 10:40 am ET in New York City.

About MELA Sciences

MELA Sciences is a medical technology company focused on developing MelaFind®. MelaFind® is a non-invasive and objective multi-spectral computer vision system designed to aid physicians in the detection of early melanoma from among clinically atypical (those having one or more clinical or historical characteristics of melanoma, such as asymmetry, border irregularity, color variegation, diameter greater than 6 millimeters, evolving, patient concern, regression, and ugly duckling) cutaneous pigmented lesions that are non-ulcerated, not bleeding, and less than 2.2 centimeters in diameter, when a physician chooses to obtain additional information before making a final decision to biopsy to rule out melanoma.

The MelaFind® Pre-Market Approval (PMA) application was filed with the U.S. Food and Drug Administration (FDA) in June 2009 and is currently under review at the FDA. On November 18, 2010 the General and Plastic Surgery Devices Panel, appointed by the U.S. Food and Drug Administration (FDA), voted by majority that, for its proposed indications, MelaFind® is safe and effective and that its benefits outweigh the risks. The FDA will take into account, among other things, the panel's recommendation in making its final approval decision. The FDA has not provided a date as to when it will make a decision regarding the MelaFind® PMA application. FDA approval is required prior to marketing MelaFind® in the United States.

For more information on MELA Sciences, visit www.melasciences.com.

Contact Information

  • For Investors:
    David Carey
    Lazar Partners, Ltd.
    646-871-8485